NEW YORK (GenomeWeb News) – British molecular diagnostics firm Osmetech has raised £5.2 million ($8.6 million) through a private placement of around 262 million new ordinary shares at a price of 2p each.

The new shares represent nearly 30 percent of the firm's now existing issued share capital. The placement was made last week.

Among the investors in the placement are the Efficacy Biotech Master Fund Ltd. and its affiliates, Gartmore and Schroder, the firm's principal shareholders, and certain new investors in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.